Imaging of brain metastases of bronchial carcinomas with 7 T MRI - initial results

Rofo. 2010 Sep;182(9):764-72. doi: 10.1055/s-0029-1245440. Epub 2010 Jun 11.

Abstract

Purpose: To compare the depiction of brain metastases of bronchial carcinomas on susceptibility-weighted and contrast-enhanced images with 7 T and at 1.5 T MRI.

Materials and methods: Twelve patients with brain metastases of bronchial carcinomas underwent 7 T and 1.5 T MRI. Minimum intensity projections (MinIP) of a 1.5 T SWI sequence (voxel size = 0.9 x 0.9 x 2.0 mm(3)) were compared to 7 T SWI MinIPs (voxel size = 0.4 x 0.4 x 1.5 mm(3)). A T 1-w 3D MPRAGE at 1.5 T (voxel size = 1 x 1 x 1 mm(3) after double-dose (DD) gadoterate meglumine, Gd-DOTA) was compared to a 7 T MPRAGE sequence (voxel size = 0.7 x 0.7 x x 0.7 mm(3), single dose (SD) Gd-DOTA) in all patients, and to DD Gd-DOTA in 6 patients after a 10 minute delay. The number of intracranial microhemorrhages in SWI MinIPs and the number of contrast-enhancing metastases in MPRAGE images were compared in each patient grouped into three size ranges (< or = 2 mm, > 2 mm and < 6 mm, > or = 6 mm) by two radiologists in consensus.

Results: In all 12 patients the 7 T SWI with spatially higher resolution allowed the identification of 87 versus 67 cerebral microhemorrhages at 1.5 T. 7 T T 1-w images after SD Gd-DOTA depicted 198 brain metastases versus 238 at 1.5 T after DD Gd-DOTA. After doubling the contrast dose in six patients, 4 additional brain metastases were identified at 7 T.

Conclusion: Our preliminary results indicate that despite the higher spatial resolution the detection of brain metastases on 7 T MPRAGE images is almost equal to 1.5 T MPRAGE images. The 7 T SWI sequence with spatially higher resolution allowed the detection of 20 % more microhemorrhages in brain metastases compared to the 1.5 T SWI sequence.

MeSH terms

  • Adult
  • Aged
  • Brain / pathology
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / pathology
  • Brain Neoplasms / secondary*
  • Carcinoma, Bronchogenic / diagnosis
  • Carcinoma, Bronchogenic / pathology
  • Carcinoma, Bronchogenic / secondary*
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / secondary*
  • Carcinoma, Small Cell / diagnosis
  • Carcinoma, Small Cell / pathology
  • Carcinoma, Small Cell / secondary*
  • Contrast Media / administration & dosage
  • Dose-Response Relationship, Drug
  • Female
  • Heterocyclic Compounds
  • Humans
  • Image Enhancement*
  • Image Processing, Computer-Assisted*
  • Infusions, Intravenous
  • Intracranial Hemorrhages / diagnosis
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / pathology
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Organometallic Compounds
  • Prospective Studies
  • Sensitivity and Specificity

Substances

  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate